Skip to main content
. 2016 Apr 11;113(17):4759–4764. doi: 10.1073/pnas.1521304113

Fig. 4.

Fig. 4.

SB334867 treatment counteracts elevation of circulating hepatic injury markers and reduction of α-MSH levels associated with steatosis and obesity. (A) SB334867 injection reduces serum ALT and GGT levels (lean, light gray bars; ob/ob, black bars; HFD, dark gray bars) in obese mice. **P < 0.005 vs. vehicle-injected lean mice; #P < 0.05 vs. SB334867-injected lean mice. (B) SB334867 injection reduces both size and number of lipid droplets in obese livers as detected by Oil Red staining. (Scale bar: 60 μm.) (C) Hepatomegaly and pale yellow discoloring in obese mice. (D) SB334867 injection reduces body weight (lean, light gray bars; ob/ob, black bars; HFD, dark gray bars) in obese mice. **P < 0.005 vs. vehicle-injected lean mice; *P < 0.05 vs. SB334867-injected lean mice; #P < 0.05 vs. vehicle-injected ob/ob or HFD mice. (E) SB334867 or AM251 injection increases serum α-MSH levels in obese mice. Data are means ± SEM; n = 6 mice per group fed ad libitum. Statistical analysis was run by two-way ANOVA followed by the Bonferroni post hoc test.